Orchard Therapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is April - March.

Millions GBP. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	338	-1	-1,038	963	-1,031	Upgrade
Depreciation & Amortization	8	8	7	5	4	Upgrade
Income (Loss) on Equity Investments	72	77	73	57	34	Upgrade
Other Operating Activities	-148	325	1,198	-780	1,142	Upgrade
Operating Cash Flow	270	409	240	245	149	Upgrade
Operating Cash Flow Growth	-33.98%	70.42%	-2.04%	64.43%	-60.27%	Upgrade
Acquisition of Real Estate Assets	-942	-370	-364	-855	-224	Upgrade
Sale of Real Estate Assets	292	390	694	477	1,073	Upgrade
Net Sale / Acq. of Real Estate Assets	-650	20	330	-378	849	Upgrade
Investment in Marketable & Equity Securities	-294	-193	-133	-135	23	Upgrade
Other Investing Activities	91	1	129	128	38	Upgrade
Investing Cash Flow	-853	-172	326	-385	910	Upgrade
Long-Term Debt Issued	633	361	20	483	214	Upgrade
Long-Term Debt Repaid	-135	-390	-337	-217	-1,225	Upgrade
Net Debt Issued (Repaid)	498	-29	-317	266	-1,011	Upgrade
Issuance of Common Stock	295	1	-	-	-	Upgrade
Common Dividends Paid	-220	-213	-213	-155	-76	Upgrade
Other Financing Activities	-21	-33	-22	-51	-11	Upgrade
Net Cash Flow	-31	-37	14	-80	-39	Upgrade
Cash Interest Paid	57	51	71	62	70	Upgrade
Cash Income Tax Paid	7	6	-	6	33	Upgrade
Levered Free Cash Flow	138.63	211.63	192.88	180.88	67.13	Upgrade
Unlevered Free Cash Flow	208.63	278.5	249.13	233.38	125.25	Upgrade

Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.